Primary Human Hepatocytes – Characterised

Primary Human Hepatocytes – Characterised

Primary Human Characterised Hepatocytes are isolated from whole human livers that are not suitable for liver transplantation.

Both plateable and suspension hepatocytes are evaluated for post-thaw yield and viability, morphology, and plating efficiency. Characterized cryoplateable human hepatocytes are also evaluated for CYP450 basal and mRNA induction levels following treatment with known inducers of CYP1A2 (Omeprazole 50μM), CYP2B6 (Phenobarbital 1mM), and CYP3A4 (Rifampicin 10μM). Each lot is guaranteed to contain a minimum of 3 million cells per vial, have a viability of > 85%, and maintain > 75% confluency for a minimum period of 5 days.

Characterized cryosuspension human hepatocytes are evaluated for the following enzymatic activity panel: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6, CYP2E1, CYP3A4 (Midazolam), CYP3A4 (Testosterone), GEN, SULT, UGT, and AO. Each lot is guaranteed to contain a minimum of 3 million cells per vial and have a viability of > 75%.

Hepatocyte lots can also be analysed for purity through FACS analysis for the cell markers: CD147, CD166, and CD45. All of the lot-specific information will be reported on the Certificate of Analysis (CoA).

Please see our protocol/lot dependent for detailed instructions. Primary Human Hepatocytes protocols do change slightly depending on the lot. Some lots need to have an additional Percoll step. Culture vessels must be coated with Type I Collagen: ax3799 is recommend.

Use ax3754-1 Primary Hepatocyte Thaw Medium and ax3752-1 Primary Hepatocyte Maintenance Medium for cryosuspension (non plateable) lots. Use ax3751-1 Primary Hepatocyte Plating Medium for Plateable lots.

All cells are tested and confirmed negative for HIV-1, HIV-2, HBV and HCV as detected by PCR. The cells are confirmed to be negative for mycoplasma and other detectable microbial contamination.